Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of Ipilimumab (Anti CTLA- 4 Antibody) in Combination With Lenalidomide (IMiD) in Patients With Advanced Malignancies

Trial Profile

A Phase I Trial of Ipilimumab (Anti CTLA- 4 Antibody) in Combination With Lenalidomide (IMiD) in Patients With Advanced Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2019

At a glance

  • Drugs Ipilimumab (Primary) ; Lenalidomide
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Cancer; Hodgkin's disease; Leiomyosarcoma; Malignant melanoma; Renal cancer; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Feb 2019 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 07 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top